TKPYY : Summary for TAKEDA PHARMACEUTI SPON ADR EA - Yahoo Finance

U.S. Markets closed

Takeda Pharmaceutical Company Limited (TKPYY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
24.29+0.22 (+0.89%)
At close: 3:53PM EDT
People also watch
ALPMYESALYDSNKYTKPHFSVNDY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close24.08
Open24.28
Bid0.00 x
Ask0.00 x
Day's Range24.27 - 24.30
52 Week Range19.96 - 25.05
Volume8,348
Avg. Volume40,619
Market Cap35.97B
Beta0.41
PE Ratio (TTM)31.98
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.78 (3.31%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Financial Times5 days ago

    [$$] Demands of disease drive vaccine science

    Vaccine research has a long history, dating back to Edward Jenner's first inoculation against smallpox in 1796. But today the field is growing vigorously, propelled by a rising world demand to fight existing ...

  • Moody's6 days ago

    Takeda Pharmaceutical Company Limited -- Moody's: Japan economic momentum building, on the back of rising exports and expected fiscal support

    Announcement: Moody's: Japan economic momentum building, on the back of rising exports and expected fiscal support. Global Credit Research- 18 Apr 2017. Tokyo, April 18, 2017-- Moody's Japan K.K. has released ...

  • Reuters19 days ago

    Takeda's largest study brings dengue vaccine step closer

    Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business. Japan's largest drugmaker has taken a conscious decision to become more international under its French CEO Christophe Weber, who took over in 2015. The international dengue study will test the experimental vaccine on 20,100 children and adolescents in eight countries in Latin America and Asia where the mosquito-borne disease is endemic.